1Jemal A,Siegel R,Ward E,et al.Cancer Statistics[J].CA Cancer J Clin,2008,58 (2):71.
2Ciardiello F,Tortora G.Drug therapy:EGFR antagonists in cancer treatment[J].N Engl J Med,2008,358(11):1160.
3Arteaga CL.The epidermal growth factor receptor:from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia[J].J Clin Oncol,2001,19(18):32.
4Wang X,Zhang S,MacLennan GT,et al.Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder[J].Clin Cancer Res,2007,13(3):953.
5Kassouf W,Black PC,Tuziak T,et al.Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer[J].Journal of Urology,2008,179(1):353.
6Chow NH,Liu HS,Lee EI,et al.Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer[J].Anticancer Res,1997,17(2):1293.
7Colquhoun AJ,Sundar S,Rajjayabun PH,et al.Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer[J].Clin Oncol (R Coll Radiol),2006,18(9):702.
8Jacobs MA,Wotkowicz C,Baumgart ED,et al.Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib[J].J Urol,2007,178(4):1510.
9Shrader M,Pino MS,Lashinger L,et al.Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression[J].Cancer Res,2007,67(4):1430.
10Nutt JE,Foster PA,Mellon JK,et al.hEGR1 is induced by EGF,inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours[J].Br J Cancer,2007,96(5):762.
二级参考文献9
1Takahashi C, Sheng Z, Horan T P, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK[J]. Proc Natl Acad Sci USA,1998,95:13221-13226.
2Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis[J]. Cell, 2001,107 : 789-800.
3Wu X, Gan B, Yoo Y, et al. FAK-mediated src phosphorylation of endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation[J]. Dev Cell, 2005,9 : 185-196.
4Masui T, Doi R, Koshiba T, et al. RECK expression in pancreatic cancer:its correlation with lower invasiveness and better prognosis[J]. Clin Cancer Res,2003,9 : 1779-1784.
5Cho C Y, Wang J H, Chang H C, et al. Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells[J]. J Cell Physiol, 2007, 213 : 65- 69.
6Chang H C, Cho C Y, Hung W C. Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer[J]. Cancer Sci, 2007,98 : 169-173.
7Takenaka K, Ishikawa S, Kawano Y, et al. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer[J]. Eur J Cancer, 2004, 40 : 1617-1623.
8Kanayama H, Yokota K, Kurokawa Y, et al. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metal loproteinase-2 expression in bladder cancer[J]. Cancer, 1998 82:1359-1366.
9Ozdemir E, Kakehi Y, Okuno H, et al. Role of matrix metal loproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas[J]. J Urol, 1999,161 : 1359-1363.
4John J. Knoedler,Stephen A. Boorjian,Simon P. Kim,Christopher J. Weight,Prabin Thapa,Robert F. Tarrell,John C. Cheville,Igor Frank.Does Partial Cystectomy Compromise Oncologic Outcomes for Patients with Bladder Cancer Compared to Radical Cystectomy? A Matched Case-Control Analysis[J].The Journal of Urology.2012(4)
5FumitakaKoga,KazunoriKihara,SoichiroYoshida,MinatoYokoyama,KazutakaSaito,HitoshiMasuda,YasuhisaFujii,SatoruKawakami.Selective bladder‐sparing protocol consisting of induction low‐dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle‐invasive bladder cancer: oncological outcomes of the initial 46 patients[J].BJU International.2012(6)
